Omnicell, Inc. (OMCL) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $36.33. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 0 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of OMCL = $781.68 (+2051.6% from the current price, the stock appears undervalued). Analyst consensus target is OMCL = $55 (+52.1% upside).
Valuation: OMCL trades at a trailing Price-to-Earnings (P/E) of 769.1 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 40.06.
Financials: revenue is $1.2B, -2.7%/yr average growth. Net income is $2M, growing at -127.6%/yr. Net profit margin is 0.2% (thin). Gross margin is 42.5% (-2.9 pp trend).
Balance sheet: total debt is $204M against $1.2B equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 1.43 (adequate). Debt-to-assets is 10.3%. Total assets: $2.0B.
Analyst outlook: 9 / 19 analysts rate OMCL as buy (47%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 39/100 (Fail), Growth 15/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 58/100 (Partial), Future 52/100 (Partial), Income 30/100 (Fail).
